251 related articles for article (PubMed ID: 23529731)
1. In vitro activity of Biapenem plus RPX7009, a carbapenem combined with a serine β-lactamase inhibitor, against anaerobic bacteria.
Goldstein EJ; Citron DM; Tyrrell KL; Merriam CV
Antimicrob Agents Chemother; 2013 Jun; 57(6):2620-30. PubMed ID: 23529731
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of biapenem (L-627), a new carbapenem, against anaerobes.
Aldridge KE; Morice N; Schiro DD
Antimicrob Agents Chemother; 1994 Apr; 38(4):889-93. PubMed ID: 8031067
[TBL] [Abstract][Full Text] [Related]
3. Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole.
Goldstein EJ; Citron DM; Cherubin CE; Hillier SL
J Antimicrob Chemother; 1993 Mar; 31(3):363-72. PubMed ID: 8486570
[TBL] [Abstract][Full Text] [Related]
4. [In vitro activity of carbapenems (biapenem, imipenem and meropenem) and some other antibiotics against strict anaerobic bacteria].
Bland S; Sedallian A; Grollier G; Mory F; Houcke I; Dubreuil L
Pathol Biol (Paris); 1995 Apr; 43(4):289-93. PubMed ID: 7567117
[TBL] [Abstract][Full Text] [Related]
5. Activity of biapenem (RPX2003) combined with the boronate β-lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae.
Livermore DM; Mushtaq S
J Antimicrob Chemother; 2013 Aug; 68(8):1825-31. PubMed ID: 23580564
[TBL] [Abstract][Full Text] [Related]
6. In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
Snydman DR; Jacobus NV; McDermott LA
Antimicrob Agents Chemother; 2008 Dec; 52(12):4492-6. PubMed ID: 18838581
[TBL] [Abstract][Full Text] [Related]
7. The growth-inhibitory properties of meropenem against anaerobes of clinical importance.
Watt B; Naden M
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():119-24. PubMed ID: 2808203
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam.
Appelbaum PC; Spangler SK; Jacobs MR
J Antimicrob Chemother; 1993 Aug; 32(2):223-31. PubMed ID: 8226424
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial activity of the new carbapenem biapenem compared to imipenem, meropenem and other broad-spectrum beta-lactam drugs.
Sader HS; Jones RN
Eur J Clin Microbiol Infect Dis; 1993 May; 12(5):384-91. PubMed ID: 8354307
[TBL] [Abstract][Full Text] [Related]
10. [Activity of doripenem against anaerobic bacteria].
Dubreuil L; Neut C; Mahieux S; Muller-Serieys C; Jean-Pierre H; Marchandin H; Soussy CJ; Miara A
Pathol Biol (Paris); 2011 Apr; 59(2):102-7. PubMed ID: 20537808
[TBL] [Abstract][Full Text] [Related]
11. Susceptibilities of 394 Bacteroides fragilis, non-B. fragilis group Bacteroides species, and Fusobacterium species to newer antimicrobial agents.
Appelbaum PC; Spangler SK; Jacobs MR
Antimicrob Agents Chemother; 1991 Jun; 35(6):1214-8. PubMed ID: 1929264
[TBL] [Abstract][Full Text] [Related]
12. Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
Liu CY; Huang YT; Liao CH; Yen LC; Lin HY; Hsueh PR
Antimicrob Agents Chemother; 2008 Sep; 52(9):3161-8. PubMed ID: 18625771
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility of anaerobic bacteria to meropenem.
Nord CE; Lindmark A; Persson I
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():113-7. PubMed ID: 2553656
[TBL] [Abstract][Full Text] [Related]
14. In vitro activities of faropenem against 579 strains of anaerobic bacteria.
Wexler HM; Molitoris D; St John S; Vu A; Read EK; Finegold SM
Antimicrob Agents Chemother; 2002 Nov; 46(11):3669-75. PubMed ID: 12384389
[TBL] [Abstract][Full Text] [Related]
15. [Can meropenem E-test be used to estimate the presence of carbapenem resistance gene cfiA among Bacteroides fragilis strains?].
Toprak Ülger N; Ilki A; Ozel N; Balkan N; Söyletir G
Mikrobiyol Bul; 2011 Jul; 45(3):385-91. PubMed ID: 21935771
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of meropenem compared with imipenem, metronidazole, ampicillin, and ampicillin/sulbactam against anaerobes.
Schumacher U; Manncke B; Gerbracht K; Werner H
Arzneimittelforschung; 1994 Jul; 44(7):859-62. PubMed ID: 7945523
[TBL] [Abstract][Full Text] [Related]
17. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
[TBL] [Abstract][Full Text] [Related]
18. In vitro antianaerobic activity of ertapenem (MK-0826) compared to seven other compounds.
Hoellman DB; Kelly LM; Credito K; Anthony L; Ednie LM; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2002 Jan; 46(1):220-4. PubMed ID: 11751138
[TBL] [Abstract][Full Text] [Related]
19. In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates.
Wexler HM; Engel AE; Glass D; Li C
Antimicrob Agents Chemother; 2005 Oct; 49(10):4413-7. PubMed ID: 16189137
[TBL] [Abstract][Full Text] [Related]
20. In vitro antimicrobial activity of razupenem (SMP-601, PTZ601) against anaerobic bacteria.
Tran CM; Tanaka K; Yamagishi Y; Goto T; Mikamo H; Watanabe K
Antimicrob Agents Chemother; 2011 May; 55(5):2398-402. PubMed ID: 21343447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
